Showing results (1-10 of 54) with videos related to
Sort By:
Pageof 6
Seminars in Hematology|June 26, 2012
Discovery and development of second-generation proteasome inhibitorsChristopher J KirkCurrent Opinion in Drug Discovery & Development|August 30, 2008
Development of proteasome inhibitors in oncology and autoimmune diseasesMark K Bennett, Christopher J KirkCurrent Opinion in Immunology|December 11, 2012
The immunoproteasome in antigen processing and other immunological functionsMichael Basler, Christopher J Kirk, Marcus GroettrupNature Reviews. Immunology|December 17, 2009
Proteasomes in immune cells: more than peptide producers?Marcus Groettrup, Christopher J Kirk, Michael BaslerCancer Biology & Therapy|June 11, 2014
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitorsYan Zang, Christopher J Kirk, Daniel E JohnsonBiochemical and Biophysical Research Communications|October 3, 2003
Alkylphenol endocrine disrupters inhibit IP3-sensitive Ca2+ channelsShahla Zafar Khan, Christopher J Kirk, Francesco MichelangeliMethods in Molecular Biology (Clifton, N.J.)|June 9, 2014
Assessment of cytokine-modulated proteasome activityChristopher J Kirk, Saul R Powell, Edmund J MillerJournal of Immunology (Baltimore, Md. : 1950)|October 21, 2011
The antiviral immune response in mice devoid of immunoproteasome activityMichael Basler, Ulrike Beck, Christopher J Kirk, et al.Cells|January 11, 2022
Discovery and Early Clinical Development of Selective Immunoproteasome InhibitorsChristopher J Kirk, Tony Muchamuel, Jinhai Wang, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 18, 2012
Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiationKhalid W Kalim, Michael Basler, Christopher J Kirk, et al.Pageof 6